Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -
Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Saturday, August 16, 2014
Friday, August 15, 2014
Why wait to receive our e-Newsletter publications?
-Creates a diversified, high-growth therapeutic portfolio, capable of delivering substantial, sustainable value for shareholders
Biogen Idec’s PLEGRIDYTM (peginterferon beta-1a) Approved for Relapsing Forms of MS - detailed information is found here
BIOGEN IDEC’S PLEGRIDY™(PEGINTERFERON BETA-1A) APPROVED IN THE US FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Cannabis-based multiple sclerosis drug approved in Wales but could be blocked in England (UK confusion?)
Thursday, August 14, 2014
Recording Date: August 9, 2014
Presented by: Brian Steingo, MD of Neurology
Provided by: MS Views and News
Video Recorded July 29th, 2014 from Boca Raton, Florida
With Brian Steingo, MD of Neurology
Video Recorded on July 29, 2014
Wednesday, August 13, 2014
Watch this easy to understand video found here
Evidence found in both human multiple sclerosis patients and experimental mouse models, according to research published in the American Journal of Pathology
Contact: Eileen Leahy
Elsevier Health Sciences
Article source found here